SUPN Q3 2025 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$192M+9.3% YoY

Gross Profit

$144M74.8% margin

Operating Income

-$60M-31.4% margin

Net Income

-$45M-23.5% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

+16.1%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$370M

Stockholders' Equity

$1.0B

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$192M	$176M	+9.3%
Gross Profit	$144M	$158M	-9.1%
Operating Income	-$60M	$41M	-247.5%
Net Income	-$45M	$38M	-217.2%

Revenue Segments

Product

$169M48%

Qelbree

$81M23%

GOCOVRI

$41M12%

Collaboration Revenue

$20M6%

Oxtellar X R

$12M3%

APOKYN

$10M3%

Trokendi Xr

$10M3%

Manufactured Product, Other

$7M2%

Royalty, License And Other Revenue

$3M1%